Trial abstract · §3
PIONEER-1 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 26 as monotherapy | Dose-dependent reduction of 0.6 to 1.1 percentage points versus placebo | High |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Semaglutide, oral from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 20.0 | 2.4 | PIONEER 1 (14 mg, 26 weeks) |
| Diarrhoea | 9.0 | 2.4 | PIONEER 1 |
| Vomiting | 7.0 | 1.2 | PIONEER 1 |
| Decreased appetite | 7.0 | 1.6 | PIONEER 1 |
| Discontinuation for adverse events | 7.3 | 2.4 | PIONEER 1 |
| Nausea | 36.5 | 12.2 | OASIS 1 (50 mg) |
| Vomiting | 24.6 | 4.2 | OASIS 1 |
Compound Evidence Institute · CEI-TR-0017/3 · https://compoundevidence.com/trials/pioneer-1/results/ · retrieved 30 July 2026